Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery
Exalpha Biologicals, Inc.

Dendritic Cell Exclusion Assay Kit - CD3/CD19/CD56/CD14 FITC

  • Product Code: X1214K
  • Size: 50 Tests
  • Price (USD): $682

Cat #

X1214K		 Quantity:      

Data Sheet

Product Name

Dendritic Cell Exclusion Assay Kit - CD3/CD19/CD56/CD14 FITC

Synonyms

CD3+CD19+CD56+CD14 FITC (IgG2a , IgG1, IgG2b, IgG2a )

Product Type

Flow Cytometry Kits

Applications

Flow Cytometry

Purification

Protein A/G Chromatography

Size

50 Tests

Price (USD)

$682

Background

The Dendritic Cell Exclusion Kit is a combination of monoclonal antibodies directed against T-lymphocytes (CD3), B-Lymphocytes (CD19), natural killer (CD56) and monocytes (CD14) all conjugated with FITC. Peripheral blood dendritic cells can be distinguished from other leucocytes by their characteristic lack of staining with this combination (1). Dendritic cells constitute a heterogeneous group of cells which play a crucial role in the immune system since they represent the most potent professional antigen-presenting cells for the initiation of immune responses. This is related to their widespread localization in all sites of antigen entry, their high expression of immunomodulatory molecules necessary for T cell activation, and their production of cytokines. In recent years there has been an increasingly high interest on the study of dendritic cells, particularly due to their possible application in immunotherapy. Accordingly, the ability of dendritic cells to stimulate primary T lymphocyte and T cell-dependent immune responses may provide opportunities for therapeutic intervention in bone marrow and solid organ transplantation, as well as in autoinmune diseases. In addition, protocols for clinical immunotherapy programmes, targeted on malignant cell antigens or infectious agents, have been designed to exploit dendritic cells as a natural adjuvant for optimal therapeutic vaccination. Dendritic cells can be identified in human peripheral blood as the fraction of nucleated cells which do not show reactivity for CD3, CD19, CD56 and CD14 antigens and which at the same time are positive for HLA-DR. At flow cytometry these cells display a typical light scatter pattern, with FSC/SSC intermediate values between lymphocytes and monocytes.

Formulation

Provided as sterile filtered solution in phosphate buffered saline with 0.08% sodium azide and 0.2% carrier protein

Customer Storage

Product should be stored at 4-8ºC. DO NOT FREEZE

Product Image

Image Legend

Normal peripheral blood sample stained with Dendritic Cells Exclusion Kit and HLA-DR-PE-Cyanine5

Database Links:

SwissProtP08571Human
SwissProtP13591Human
SwissProtP15391Human
SwissProtP07766Human

References

1. Almeida J, Bueno C, Alguero MC, Sanchez ML, Can?izo MC, Fernandez ME, Vaquero JM, Laso FJ, Escribano L, San Miguel JF, Orfao A. Extensive characterization of the immunophenotype and pattern of cytokine production by distinct subpopulations of normal human peripheral blood MHC II+/lineage- cells. Clin Exp Immunol. 1999 Dec;118(3):392-401. 2. Protection of Laboratory Workers from occupationally acquired infections. Second edition; approved guideline (2001). Villanova PA: National Committee for Clinical Laboratory Standards; Document M29-A2. 3. Procedures for the collection of diagnostic blood specimens by venipuncture- approved standard; Fifth edition (2003). Wayne PA: National Committee for Clinical Laboratory Standards; Document H3-A5. 4. Clinical applications of flow cytometry: Quality assurance and immunophenotyping of lymphocytes; approved guideline (1998). Wayne PA: National Committee for Clinical Laboratory Standards; Document H42-A.